Literature DB >> 17535196

Use of infliximab in pyoderma gangrenosum.

Daniel Hewitt1, Clare Tait.   

Abstract

A 57-year-old man, with a 2-year history of Crohn's disease, presented with a rapidly progressive abdominal ulcer. It was clinically and histologically consistent with pyoderma gangrenosum but it did not respond to either high-dose oral prednisolone or intravenous hydrocortisone. Infliximab resulted in an early, dramatic and sustained improvement. His bowel symptoms, which flared a few weeks prior to the onset of pyoderma gangrenosum, only partially improved. Despite six infliximab infusions, the inflammatory bowel disease is poorly controlled, whereas the pyoderma gangrenosum remains healed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17535196     DOI: 10.1111/j.1440-0960.2007.00344.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  4 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

2.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

Review 3.  Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status.

Authors:  Kentaro Tominaga; Kenya Kamimura; Hiroki Sato; Masayoshi Ko; Yuzo Kawata; Takeshi Mizusawa; Junji Yokoyama; Shuji Terai
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

4.  Pyoderma gangrenosum with monoclonal IgA gammopathy and pulmonary tuberculosis. Illustrative case and review.

Authors:  Krystyna Romańska-Gocka; Czanita Cieścińska; Barbara Zegarska; Robert A Schwartz; Jakub Cieściński; Dorota Olszewska-Słonina; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2015-03-30       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.